OGN logo

OGN Organon & Co.

New York Stock Exchange · Drug Manufacturers - General · Healthcare

$13.89
-0.02 (-0.14%)

Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenz…

Market Cap: $3.65Bwww.organon.com

Price

No data yet.

Social Signal Score

51
5d
—
30d
55
4 mentions
—
60d
48
10 mentions
—
90d
49
13 mentions
—
news: 13

Analyst Ratings

9 analysts
Holdconsensus
Strong Buy 0Buy 2Hold 4Sell 3Strong Sell 0
Avg price target$11.33-18.4%
Low $8Median $12High $14
Current Consensus

Revenue

$1.57B-11.57%
$1.46B$1.57B$1.67B$1.78B
Mar 2020Sep 2026

Analyst Estimates

FY2025
$3.75
$3.62–$3.84
6 analysts
FY2026
$3.35-11% YoY
$3.31–$3.40
2 analysts
FY2027
$3.63+8% YoY
$3.45–$3.84
2 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Joseph T. Morrissey Jr.
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
10,000
Beta
1.49
Country
US
Piotroski score
7 / 9 (Strong)
Altman Z-score
1.27
www.organon.com